SCHEMBL863987

SCHEMBL863987

CCn1ccc2cc(-c3ccc4nnc(-c5ccccc5)n4n3)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 6/20 0.46
HSD11B1 P28845 1/20 0.44
KDM4E B2RXH2 3/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
BRD4 O60885 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA2B P29275 1/20 0.43
ADORA1 P30542 1/20 0.43
CREBBP Q92793 1/20 0.43
FAAH O00519 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL863990 0.81 MET (0.42) METKDM4ELMNAMAPTHTT
SCHEMBL863591 0.78 MET (0.45) METKDM4ELMNAMAPTHTT
SCHEMBL2646931 0.75 KDM4E (0.67) METKDM4ELMNAMAPTHTT
SCHEMBL16174469 0.74 MET (0.43) METKDM4ELMNAMAPTHTT
SCHEMBL863630 0.73 NPC1 (0.52) KDM4EHPGDHSD17B10BRD4ADORA3
SCHEMBL4781296 0.70 LRRK2 (0.47) METKDM4EMAPTHPGDHSD17B10
SCHEMBL19626756 0.67 ALDH1A1 (0.49) KDM4EMAPTHPGDHSD17B10FAAH
SCHEMBL16174464 0.67 MAOB (0.43) METHSD11B1BRD4FAAHGABRA1
SCHEMBL11489169 0.65 KDM4E (0.65) KDM4ELMNAHTTHPGDHSD17B10
SCHEMBL17626320 0.65 FAAH (0.41) FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865719-B2 Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-10-21 US disclosed
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS CHRNA7, CHRNA5, CHRNA1 MET 4368/4885HSD11B1 1613/4885KDM4E 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.